Olubusola Oluwole

Olubusola Oluwole

Auto-generated profile, based on publicly available information

Olubusola Oluwole

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Blood
Verified
Journal Article
Closed access
OOOlubusola Oluwole
Olubusola Oluwole
ABAnn M. Brunson
Ann M. Brunson
OAOyebimpe O. Adesina
Oyebimpe O. Adesina
SWShaina M. Willen
Shaina M. Willen
TKTheresa H. M. Keegan
Theresa H. M. Keegan
TWTed Wun
Ted Wun
Neurovascular complications, including strokes and transient ischemic attacks (TIAs), are common and cause significant morbidity in individuals with sickle cell disease (SCD). The Stroke Prevention Trial in Sickle Cell Anemia (STOP) (1998) established chronic transfusions as the standard of care for children with SCD at high risk for stroke. Using statewide data from the California Department of Health Care Access and Innovation (1991-2019), we determined the cumulative incidence (CMI) and rates of primary and recurrent strokes/TIAs in people with SCD pre- and post-STOP trial. For the 7636 patients included in our SCD cohort, the cumulative incidence of the first ischemic stroke was 2.1% by the age of 20 years and 13.5% by the age of 60 years. The CMI of the first intracranial hemorrhage (ICH) was 0.5% and 6.8% by the age of 20 and 60 years, respectively. Ischemic stroke rates increased in children (age <18 years; 234.9 vs 165.1 per 100 000 patient years [PY]; P = .012) and adults (age 31-50 years; 431.1 vs 303.2 per 100 000 PY; P = .031) in 2010 to 2019 when compared with the preceding decade. There was an increase in the rates of ICH in those aged 18 to 30 years and TIA in children <18 years from 2010 to 2019 when compared with the previous decade. Risk factors for strokes included increasing age, hypertension, and hyperlipidemia. These findings underscore the need for stroke prevention in adults with SCD, suggesting an emphasis on management of modifiable cerebrovascular risk factors that have been proven to be effective in the general population.

17 March 2025 in JMIR Human Factors
Verified
Journal Article
Open access
OOOlubusola B. Oluwole
Olubusola B. Oluwole
LMLakeya McGill
Lakeya McGill
KGKadeem Gayle
Kadeem Gayle
JOJulia A. O'BRien
Julia A. O'BRien
KAKaleab Abebe
Kaleab Abebe
MHMegan Hamm
Megan Hamm
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Chronic pain is prevalent among adults with sickle cell disease (SCD) and can be worsened by psychosocial factors such as depression and inadequate social support. Effective behavioral interventions (i.e., cognitive behavioral therapy, CBT) exist for chronic pain in various populations; however, few have been developed to address chronic pain in SCD. Several barriers have restricted the development and dissemination of CBT pain interventions in SCD, such as limited accessibility and time constraints. Digital interventions provide accessible and cost-effective pain management tools, offering self-management strategies, real-time monitoring, and personalized treatment options. Yet, there is limited data regarding patients’ experiences with such intervention within the sickle cell population. The Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults with Sickle Cell Disease (CaRISMA, clinicaltrials.gov NCT04419168) trial evaluated the effectiveness of a digital CBT intervention compared to a digital educational intervention for pain management in SCD. Objective: This study aimed to gain a deeper understanding of the lived experiences of participants in the CaRISMA trial and to determine how to better adapt this intervention to SCD population. The study examined individuals’ overall experience with the trial and their perspectives of the trial components, including a health coach, a chatbot-delivered digital CBT program, and an electronic pain diary. Methods: Respondents were randomly selected to participate in semi-structured interviews at 1) baseline, 2) at the end of the intervention period at 3 months, and 3) post-intervention timepoint, 6 months or beyond. Interviews were audiotaped, transcribed verbatim, and analyzed using thematic analysis. Results: A total of 48 participants (68.8% F, n=33) completed baseline interviews. Among them, 21 participants took part in mid-trial interviews, and 17 completed post-intervention interviews. Participants generally had a positive experience, highlighting the safe space the study provided to speak openly about SCD. Many found value in learning about the connection between pain and mental health, considering it an important aspect of their well-being. Feedback indicated that the health coach played a key role in offering personalized support and guidance. While the chatbot reinforced pain management strategies, its usefulness and engagement varied based on participants’ prior knowledge of SCD. The pain diary helped increase self-awareness of pain patterns, but was perceived as tedious and irrelevant by those without current pain episodes. Conclusions: The CaRISMA trial showed that participants valued the personalized support of the health coach, education about the connection between stress and pain, and the self-reflection fostered by the pain diary. These findings highlight the potential of digital, patient-centered approaches to address the multifaceted needs of SCD care. For digital interventions, the inclusion of personalized support with ongoing communication appears to be critical component that can influence treatment adherence and effectiveness. Clinical Trial: clinicaltrials.gov NCT04419168

1 May 2026 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
MOModesty Obasohan
Modesty Obasohan
EAEugenia Vicky Asare
Eugenia Vicky Asare
CJCharles Jonassaint
Charles Jonassaint
AOAmma T Owusu-Ansah
Amma T Owusu-Ansah
CSCatherine Segbefia
Catherine Segbefia
OOOlubusola Oluwole
Olubusola Oluwole
Purpose: Pain is the most common symptom in sickle cell disease (SCD). Due to a lack of objective markers, pain assessment relies on patient report, which can be highly subjective and lead to miscommunications regarding care. While digital pain tools show promise for improving pain communication, digital literacy barriers and cultural differences may limit their use, particularly in low-resource settings. There is a lack of data on the effectiveness of digital pain tools in sub-Saharan Africa, the region with the highest burden of SCD. Painimation is a digital application that uses animations and graphical images to assess pain location, quality, and intensity. We evaluated its feasibility, acceptability, and utility in a Ghanaian SCD cohort. Patients and Methods: This cross-sectional study was conducted at Korle-Bu Teaching Hospital in Ghana. Individuals age > 10 years with SCD were recruited from the pediatric and adult SCD clinics. Participants were asked to use Painimation and complete a clinical history and an 11-item questionnaire addressing the feasibility, utility, and acceptability of the app. Results: Of the 38 consented patients (66% female, median age: 16 years), 87% reported being comfortable using the touchscreen, and 74% said the app was easy to use. Most participants (68%) reported the app was not burdensome to complete during a pain episode. Participants reported that the body shading (92%), animation selection (92%), and intensity adjustment (87%) features were useful for communicating pain. The app took 102 seconds to complete on average. The most commonly selected pain animation was throbbing (50%), and the most frequently reported pain locations were the legs (35%), back (42%), arms (35%), and chest (35%). Conclusion: Painimation was feasible, acceptable, and useful for pain reporting in this Ghanaian SCD cohort. Pain reports using Painimation mirrored known SCD pain profiles, with predominant throbbing pain and frequent leg and back involvement. Digital health tools may improve pain assessment and management in low-resource settings in sub-Saharan Africa.

12 January 2026 in Blood Red Cells & Iron
Verified
Journal Article
Open access
CSChristine Saber
Christine Saber
JTJohn K. Tukakira
John K. Tukakira
NKNelly K. Kiriza
Nelly K. Kiriza
OOOlubusola B. Oluwole
Olubusola B. Oluwole
LCLaura M. De Castro
Laura M. De Castro
JXJulia Z. Xu
Julia Z. Xu

31 January 2024
Verified
Preprint
Open access
OOOlubusola Oluwole
Olubusola Oluwole
MAMary Ampomah
Mary Ampomah
AOAmma Owusu-Ansah
Amma Owusu-Ansah
MNMehdi Nouraie
Mehdi Nouraie
CSCatherine Segbefia
Catherine Segbefia
ENEnrico Novelli
Enrico Novelli
Background: In sickle cell disease (SCD), cognitive impairment is a manifestation of end organ damage with devastating functional effects. Sub-Saharan Africa accounts for the highest annual SCD burden in the world, yet little is known about cognitive impairment in children from Africa with SCD. Additionally, it is unknown if hydroxyurea, the first FDA-approved drug for SCD, preserves cognitive functioning. The primary objective of this study was to assess the potential cognitive benefits of hydroxyurea administered for ≥ 1 year in children with SCD from Ghana. Methods: We conducted a cross-sectional study at Korle Bu Teaching Hospital in Ghana. The cognitive functioning (psychomotor function, attention, working memory and executive function) of children with SCD (aged 5-13 years) on hydroxyurea (cases) was compared to that of an age-matched group not on hydroxyurea (controls). Results: Children taking hydroxyurea (n=30) had higher hemoglobin (mean 9.34 vs 8.32 g/dL, P=0.012) and red blood cell mean corpuscular volume (mean 94 vs 77 fL, P<0.001) when compared to the non-hydroxyurea group (n=28). Children in the hydroxyurea group performed significantly better in the area of working memory (adjusted difference -0.06, p=0.03), while there was no significant difference in the other domains. Conclusion: To our knowledge, this is the first study conducted in Africa exploring the impact of hydroxyurea on cognitive functioning. While causality cannot be inferred in this observational study, our results suggest that hydroxyurea may improve cognitive functioning. Future longitudinal and interventional studies are needed to further assess potential cognitive benefits of hydroxyurea, particularly in sub-Saharan Africa.

7 January 2026 in Annals of Behavioral Medicine
Verified
Journal Article
Open access
OOOlubusola B Oluwole
Olubusola B Oluwole
YCYi-Fan Chen
Yi-Fan Chen
CLChristina M Lalama
Christina M Lalama
JOJulia A O’BRien
Julia A O’BRien
LCLaura M De Castro
Laura M De Castro
CJCharles R Jonassaint
Charles R Jonassaint
Background: Chronic pain affects up to 40% of adults with sickle cell disease (SCD), yet treatment options remain limited. While cognitive behavioral therapy (CBT) is effective in other chronic pain conditions, it is underutilized for SCD pain, and its effectiveness remains unclear. Purpose: The Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) compared digital CBT to Education for chronic SCD pain in adults. At 6 months, the primary outcome (pain interference) showed no between-group difference but both groups improved (CBT: −2.13; Education: −2.66). This report presents 12-month outcomes. Methods: A total of 359 participants with SCD chronic pain were randomized to 12 weeks of digital CBT (n = 181) or Education (n = 178), both with weekly health coach support. Results: At 12 months, 56.5% (n = 203) completed follow-up. No between-group differences in pain interference were observed [0.43, 95% CI, −1.61 to 2.48; P = .68]; however, both groups sustained improvement from baseline (CBT: −1.50; Education: −1.93). Cognitive behavioral therapy participants reported greater improvement in emotional impact [2.00, 95% CI, 0.12-3.88; P = .04], while pain intensity, depression, anxiety, and opioid misuse did not differ between groups. Higher health coach engagement was associated with reduced pain interference [−0.073 per 10% increase in engagement; P < .01]. Conclusions: Although no between-group differences were found, both groups showed sustained improvement in pain interference at 12 months. Personalized support may have contributed to these improvements, highlighting the value of human support within digital interventions. Further research is needed to clarify the relative contributions of digital CBT vs human support. Study registration: This trial was registered on ClinicalTrials.gov (Identifier: NCT04419168. Registered 06/05/2020). Analytic plan registration: The trial protocol and analytic plan were pre-registered and are publicly available (https://www.researchprotocols.org/2021/5/e29014).